This paper discusses the current status and challenges of clinical investigation regarding antiplatelet and thrombolytic therapies for myocardial infarction.
Challenges in MI antiplatelet and thrombolytic therapies warrant clinical caution; leaves open optimal regimens for targeted trials.
ON MANY FRONTS, both prophylactic and therapeutic, major efforts have been or are about to be undertaken to decrease what some have termed the "epidemic" of coronary artery disease and acute myocardial infarction in our society. The difficulties confronting the clinical investigator who wishes to mount a meaningful therapeutic attack on this problem are great and stem from several sources.
No takes yet. Share an insight, caveat, or question.
Wessler et al. (1972) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: